检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:樊志明[1] 黄超红[1] 贺红桂[1] 郑宏莹[1]
机构地区:[1]中国人民解放军第四二二医院肿瘤科,广东湛江524000
出 处:《海南医学》2013年第4期536-538,共3页Hainan Medical Journal
摘 要:目的分析C反应蛋白水平与非小细胞肺癌患者(NSCLC)远期预后的相关性。方法选择126例非小细胞肺癌患者,设为NSCLC组,同期健康体检者126例设为对照组,测定两组受试者的血清C反应蛋白水平,随访NSCLC组1-5年,观察C反应蛋白水平与非小细胞肺癌患者远期预后的相关性。结果NSCLC组水平明显高于对照组患者;NSCLC组术后CRP水平显著下降,上述比较差异均具有统计学意义(P〈0.05)。随着CRP的升高,肿瘤分期上升,而两组高低组间1年生存率差异无统计学意义,低CRP水平组3年、5年生存率明显高于高CRP水平组,组间差异有统计学意义(P〈0.05)。结论C反应蛋白水平与非小细胞肺癌患者远期预后有密切的相关性,对推测术后NSCLC患者的远期预后具有重要意义。Objective To analyze the correlation between C-reactive protein (CRP) levels and long-term prognosis of patients with non-small cell lung cancer. Methods One hundred and twenty-six patients of non-small cell lung cancer were enrolled as the NSCLC group, and 126 healthy volunteers were selected as the control group. The serum levels of CRP were measured. The patients were followed up for 1-5 years, the correlation between CRP levels and the long-term prognosis of patients with non-small cell lung cancer patients was investigated. Results The levels of CRP in the NSCLC group were significantly higher than those in the control group (P 〈 0.05). The CRP lev- els of the NSCLC group decreased significantly after surgery (P〈0.05). As the increase of CRP levels, the tumor stage progressed. The one-year survival rate showed no statistically significantly difference between the high CRP level group and the low CRP level group (P〉0.05). The 3-year survival rate and 5-year survival rate in the low CRP level group were significantly higher than those in the high CRP level group (P〈0.05). Conclusion C-reactive protein levels are closely correlated with the long-term prognosis of patients with non-small cell lung cancer, which is of great importance for evaluating the long-term prognosis of patients with NSCLC after surgery.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15